Table 4 Evaluation of treatment efficacy in patients with cardiac metastases who continued treatment
From: Clinical features and prognosis of cardiac metastatic tumors
ID | Age | Lymphoma | Status | Cardiac symptoms | Pericardial effusion | NT-proBNP | Clinical efficacy | Possible cause of death | ||
|---|---|---|---|---|---|---|---|---|---|---|
Original tumor | Cardiac metastases | Other metastases | ||||||||
1 | 48 | Yes | Died | Yes | No | 142002.00 | SD | SD | SD | Heart failure |
2 | 51 | Yes | Died | Yes | No | 1934.00 | PR | PR | SD | Tumor |
3 | 60 | No | Alive | No | No | - | CR | PR | CR | - |
5 | 46 | No | Died | Yes | No | 857.70 | PD | PD | PD | Tumor |
6 | 21 | No | Died | Yes | Yes | - | PR | PD | PD | Tumor |
7 | 63 | Yes | Died | No | No | - | CR | CR | CR | Tumor |
8 | 73 | Yes | Died | No | No | 1767.00 | SD | PR | SD | Tumor |
9 | 66 | No | Died | Yes | Yes | 1305.00 | \ | \ | \ | Tumor |
10 | 57 | Yes | Alive | No | No | 23.25 | PR | CR | PR | - |
11 | 67 | Yes | Died | No | Yes | 1426.00 | PD | SD | PD | Tumor |
12 | 66 | Yes | Died | Yes | No | 3211.00 | \ | \ | \ | - |
13 | 29 | No | Died | No | No | 1918.00 | SD | SD | PD | Tumor |
14 | 35 | No | Alive | Yes | Yes | 294.30 | SD | SD | SD | - |
15 | 59 | No | Died | No | No | - | SD | SD | PD | Tumor |
18 | 69 | No | Died | No | Yes | - | \ | \ | \ | Tumor |
19 | 52 | No | Died | No | No | 285.50 | \ | \ | \ | Tumor |
23 | 60 | No | Died | No | No | 5234.00 | SD | PD | PD | Heart failure |
24 | 66 | No | Alive | Yes | No | 14393.00 | SD | \ | \ | - |
28 | 65 | No | Died | No | No | - | SD | SD | SD | Tumor |
29 | 72 | No | Died | Yes | Yes | 7808.00 | SD | SD | SD | Heart failure |
32 | 46 | No | Alive | No | No | 334.8 | PR | PR | PR | - |
33 | 19 | No | Died | Yes | Yes | - | PD | \ | \ | Tumor |
35 | 57 | Yes | Alive | No | No | - | PR | CR | PR | - |
36 | 13 | Yes | Alive | No | No | - | CR | CR | CR | - |
37 | 73 | No | Died | Yes | No | - | SD | \ | \ | Tumor |
40 | 66 | No | Alive | No | Yes | - | SD | \ | \ | - |
41 | 59 | No | Alive | No | Yes | - | PR | CR | PR | - |